NEW YORK (360Dx) – Ascenda Biosciences said today that it has acquired proteomic diagnostic firm Provista Diagnostics.
With the purchase, Alpharetta, Georgia-based Ascenda acquired New York City-headquartered Provista's Videssa Breast test, a blood-based proteomic test for assessing whether women with indeterminate mammogram readings should receive a biopsy or can be safely monitored without immediate follow-up.
A portfolio company of private equity firm The Strategic Group, Ascenda is primarily focused on gastrointestinal testing panels and offers stool-based testing for a variety of microorganisms including pathogenic organisms like Helicobacter pylori.
Uriel Kusiatin, Provista's CFO and interim CEO will be joining Ascenda as CEO and Rao Mulpuri, Provista's COO, will become Ascenda's COO.
"We look forward to bringing our extensive knowledge, experience, and products into the Ascenda BioSciences fold, and being part of Ascenda BioSciences’ cutting-edge advanced suite of proprietary medical, genetic, and diagnostic testing," Kusiatin said in a statement.
Financial and other terms of the acquisition were not disclosed.